CRBU - Caribou Biosciences Inc logo

Caribou Biosciences Inc

CRBU

Caribou Biosciences develops CRISPR genome-editing technologies and allogeneic cell therapies for oncology. Its pipeline includes Vispacabtagene Regedleucel for B cell non-Hodgkin lymphoma and CB-011 for multiple myeloma, both in phase 1 trials.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$55today

Score Overview

1 Year
Score
Net Growth10.06%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth0.39%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.8
Net Growth-99.06%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth16.72%
Rev Trend80%
Revenue Consistencyโ€”
All Time
Score
Net Growth-99.06%
Net Trend40%
Net Income Consistency
Rev Growth16.72%
Rev Trend80%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Caribou Biosciences Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. CRBU does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-01
$ 1.22โ€”
1 Year2025-10-01
$ 2.26-46.02%
5 Years2021-10-01
$ 22.31-94.53%
All Time2021-07-23
$ 16.32-92.52%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 11M-$ 133M$ 117M
2025$ 11M-$ 148M$ 139M
2024$ 9M-$ 149M$ 209M
2023$ 34M-$ 102M$ 328M
2022$ 13M-$ 99M$ 247M
IPO2021$ 9M-$ 66M$ 375M
CRBU - Caribou Biosciences Inc logo

Caribou Biosciences Inc fundamental performance

Between 2021 and 2025, revenue grew from $ 9M to $ 11M and net income went from -$ 66M to -$ 148M. Revenue increased in 80% of the years measured; net income in 40%.

Caribou Biosciences Inc currently holds a 5-year HDB Score of 3.8 out of 10. How the HDB Score is calculated.

Membership

Explore CRBU with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,813 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies